Overall I thought the update was reasonably well done also. I found there to be a higher quality of information than we are used to, certainly had the feel of Eversana's influence all over it. I appreciated the greater insight into the covid picture for sure. Still would like to see some participation from the company science team in these updates  

I agree Texbraska, he should have probably left the 85 cent thing alone. When you tell shareholders after the end point miss of BoM that the EV of the company is "about $4B" USD and you have presided over a management/BoD team that has whittled the market cap down to about $120M CAN despite apparently growing opportunities, well that certainly screams "lousy management/governance".  To be a bit indignant about only doing financings which values a $4B asset at about $200M is nothing to be proud of. 

Overall though I feel much more optimistic about the covid program and if it turns out to be a big success the company should have no more financial troubles. That would be great for shareholders and a very welcome change IMO.